Navigation Links
SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
Date:7/26/2011

nd 49,816,073 issued and outstanding as of June 30, 2011, and December 31, 2010

49

49Additional paid-in capital

77,989

77,041Accumulated deficit

(75,810)

(74,049)Total stockholders' equity

2,228

3,041$  3,178

$  3,858(1) restated SCOLR Pharma, Inc.UNAUDITED CONDENSED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)Three months endedJune 30,Six months endedJune 30,20112010(1)20112010(1)RevenuesLicensing fees$

-$

100$

-$

125Royalty income812374264Research and development --118-   Total revenues8223192389Operating expensesMarketing and selling5386178145Research and development(103)256544596General and administrative5855721,3251,173Total operating expenses5359142,0471,914Loss from operations(527)(691)(1,855)(1,525)Other income (expense)Interest income--11Interest expense(5)-(5)-Unrealized gain (loss) on fair value of warrant(8)225977Other1(15)1(15)Total other income (expense)(12)21094(7)Net loss$

(539)$

(481)$

(1,761)$

(1,532)Net loss per share, basic and diluted$

(0.01)$

(0.01)$

(0.04)$

(0.03)Shares used in computing basic and diluted net loss per share49,81649,68449,81646,430(1) restated Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
2. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
3. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
4. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
5. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
6. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
7. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
8. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
9. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
10. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Shire plc (LSE: SHP, Nasdaq: ... a study showing that coadministration of the ADHD medication VYVANSE(R) ... OTC(R) 40 mg (20 mg X 2), did not alter ... d -amphetamine to be reached in the subjects evaluated. ...
... trials begin enrollment in May 2009; Reinforces Lilly,s commitment ... 21 Eli Lilly and Company (NYSE: ... this month in two separate but identical Phase III ... an anti-amyloid beta monoclonal antibody being investigated as a ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... Components Corporation (ICC), an established global leader in ... a new series of high-efficiency AC-DC external power ... devices. Marketed under the Elpac Power Systems brand, ... company,s rapidly expanding portfolio of high-efficiency, high-reliability power ...
... Now Have Access to Low-Price Generic Options, Helping Consumers ... Stores Inc. (WMT) today announced its list of up ... will now be accessible to physicians using an Epocrates ... device. Physicians will now be better equipped to ...
... in Light of Economic Downturn, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... efforts in Louisiana and Rhode Island will likely ... downturn, particularly as Medicaid populations grow.According to the ...
... MOUNTAIN VIEW, Calif., Feb. 19 Based on its ... Frost & Sullivan recognizes Horphag Research Ltd. with the ... of the Year Award. The award acknowledges the company,s ... 40 years, aimed at validating the health benefits of ...
... Inc. (Nasdaq: CADX ) announced today that it ... shares of the Company,s common stock at a price of ... approximately 6 million additional shares of the Company,s common stock, ... of $7.84 per share, for aggregate gross proceeds of approximately ...
... - Defyrus Inc. today announced the signing an ... by the United Kingdom,s Defence Science and Technology ... Dstl,s commercialization company. These patents form the intellectual ... programs. Defyrus and Ploughshare Innovation Ltd plan to ...
Cached Medicine News:Health News:Elpac Power System 150-Watt Commercial External Power Supply Features Industry-Leading Efficiency and Power Density 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 3Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 2Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 4Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 3Health News:Vaccine patent portfolio licensed from UK Ministry of Defence 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: